skip to main content
Idioma:

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

Myers, Robert P. ; Pomier-Layrargues, Gilles ; Kirsch, Richard ; Pollett, Aaron ; Duarte-Rojo, Andres ; Wong, David ; Beaton, Melanie ; Levstik, Mark ; Crotty, Pam ; Elkashab, Magdy

Hepatology (Baltimore, Md.), 2012-01, Vol.55 (1), p.199-208 [Revista revisada por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponible

Citas Citado por
  • Título:
    Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients
  • Autor: Myers, Robert P. ; Pomier-Layrargues, Gilles ; Kirsch, Richard ; Pollett, Aaron ; Duarte-Rojo, Andres ; Wong, David ; Beaton, Melanie ; Levstik, Mark ; Crotty, Pam ; Elkashab, Magdy
  • Materias: Adult ; Biological and medical sciences ; Biopsy ; Elasticity Imaging Techniques - instrumentation ; Elasticity Imaging Techniques - methods ; Elasticity Imaging Techniques - standards ; Fatty Liver - pathology ; Feasibility Studies ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatology ; Humans ; Liver - pathology ; Liver cirrhosis ; Liver diseases ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; Obesity ; Obesity - pathology ; Overweight - pathology ; Prospective Studies ; Reference Standards ; Reproducibility of Results
  • Es parte de: Hepatology (Baltimore, Md.), 2012-01, Vol.55 (1), p.199-208
  • Notas: istex:6FC7DF73037740627737D371B4C893CADB0F55A6
    Potential conflict of interest: Dr. Myers consults for GE Healthcare. He is in the speakers' bureau of HNS Canada and received grants from Echosens. Dr. Pomier-Layrargues received grants from Echosens and Bristol-Myers Squibb.
    ark:/67375/WNG-3XVCBHJN-P
    ArticleID:HEP24624
    Dr. Myers is supported by a Clinical Investigator Award from the Alberta Heritage Foundation for Medical Research (now Alberta Innovates - Health Solutions) and New Investigator Award from the Canadian Institutes for Health Research. The study was sponsored by Echosens (Paris, France).
    Dr. Myers is supported by a Clinical Investigator Award from the Alberta Heritage Foundation for Medical Research (now Alberta Innovates – Health Solutions) and New Investigator Award from the Canadian Institutes for Health Research. The study was sponsored by Echosens (Paris, France).
    Potential conflict of interest: Dr. Myers consults for GE Healthcare. He is in the speakers' bureau of HNS Canada and received grants from Echosens. Dr. Pomier‐Layrargues received grants from Echosens and Bristol‐Myers Squibb.
    fax: 403‐592‐5090
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    ObjectType-Article-2
    ObjectType-Feature-1
  • Descripción: Failure of liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) and unreliable results occur in ≈5% and 15% of patients, respectively, mainly due to obesity. In this multicenter study, we evaluated the feasibility and performance of the novel FibroScan XL probe in 276 patients with chronic liver disease (42% viral hepatitis, 46% nonalcoholic fatty liver disease [NAFLD]) and a body mass index (BMI) ≥28 kg/m2. Patients underwent liver biopsy and TE with the standard M and XL probes. TE failure was defined as no valid LSMs and unreliable examinations as <10 valid LSMs or an interquartile range (IQR)/LSM >30% or success rate <60%. Probe performance for diagnosing ≥F2 fibrosis and cirrhosis (F4) versus biopsy were examined using areas under receiver operating characteristic curves (AUROC). FibroScan failure was less frequent with the XL probe than the M probe (1.1% versus 16%) and the XL probe was more often reliable (73% versus 50%; both P < 0.00005). Reliable results with the XL probe were obtained in 61% of patients in whom the M probe was unreliable. Among 178 patients with ≥10 valid LSMs using both probes, liver stiffness was highly correlated between probes (ρ = 0.86; P < 0.0005); however, median liver stiffness was lower using the XL probe (6.8 versus 7.8 kPa; P < 0.00005). The AUROC of the XL and M probes were similar for ≥F2 fibrosis (0.83 versus 0.86; P = 0.19) and cirrhosis (0.94 versus 0.91; P = 0.28). Conclusion: Compared with the M probe, the FibroScan XL probe reduces TE failure and facilitates reliable LSM in obese patients. Although the probes have comparable accuracy, lower liver stiffness cutoffs will be necessary when the XL probe is used to noninvasively assess liver fibrosis. (HEPATOLOGY 2012)
  • Editor: Hoboken: Wiley Subscription Services, Inc., A Wiley Company
  • Idioma: Inglés
Enlaces
Volver a la lista de resultados
Ir a la página anteriorAnterior Resultado  8 SiguienteIr a la siguiente página

  • Realización: ABCD-USP USP   Logos de Redes Sociales: Freepik

Buscando en bases de datos remotas, por favor espere

  • Buscando por
  • enscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
  • Mostrar lo que tiene hasta ahora